약학회지
YAKHAK HOEJI
ISSN 0377-9556 (PRINT)
ISSN 2383-9457 (ONLINE)

Table. 4.

Table. 4.

Celltrion and Samsung Bioepis’s approval status of biosimilar recombinant antibodies in Europe

Manufactures Brand name Original medicines Approval date Remarks
Celltrion Remsima Remicade 2013. 08 First Biosimilar
Truxima Mabthera 2017. 02 First Biosimilar
Herzuma Herceptine 2018. 02

Samsung Bioepis Benepali Enbrel 2016. 01 First Biosimilar
Flixabi Remicade 2016. 05
Ontruzant Herceptine 2017. 11 First Biosimilar
Imraldi Humira 2017. 08
Rusuduna(SB9) Rantus 2017. 01 Partial support item for development cost from MSD

Yakhak Hoeji 2021;65:1-9 https://doi.org/10.17480/psk.2021.65.1.1
© 2021 Yakhak Hoeji